Points to remember
- Boston Scientific has reported positive results in a study of its atrial fibrillation device.
- The Farapulse uses electric fields, rather than traditional heat and cold, to treat patients.
- News sent stock. at their highest level in over a month.
Boston Scientific (BSX) was the top performing stock in the S&P 500 after the medical device maker announced positive results from a clinical trial for its system for treating patients with atrial fibrillation (AF) . .
Farapulse Pulsed Field Ablation (PFA) uses electric fields to remove heart tissue causing irregular heartbeats, rather than the more traditional thermal method. The study involved 607 patients with paroxysmal AF who had previously been unsuccessfully treated with at least one anti-arrhythmic drug.
The data showed that the Farapulse worked as well as standard therapies, meeting key criteria for efficacy and safety, the company said.
Kenneth Stein, senior vice president and global chief medical officer of Boston Scientific, said the results “underscore the superior procedural efficiency of this new technology.” Farapulse's performance is “an encouraging sign of the device's potential use in the United States,” he said. he said.
Stein indicated that 39;further studies were planned.
Boston Scientific shares have hit their highest level since July on the news.
0 .png” />YCharts. Do you have any news advice for Investopedia reporters? Please email us at email@example.com